Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
5 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 5 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.

Nitrogen-containing bisphosphonates may lower risk of pneumonia in patients with hip fracture

Dr Margaret Shi
18 Aug 2020

N-BP 2
A recent study led by researchers from the University of Hong Kong (HKU) shows that the use of nitrogen-containing bisphosphonates (N-BPs), particularly alendronate, is associated with reduced risks of pneumonia and pneumonia mortality compared with no anti-osteoporotic treatment and non-N-BP anti-osteoporotic treatment.

In the retrospective cohort study, data of 54,047 patients aged ≥50 years with an incident hip fracture who were admitted to hospital via an emergency room between 1 January 2005 and 31 December 2015, and who were diagnosed with or died of pneumonia, were retrieved from the Clinical Data Analysis and Reporting System (CDARS), a population-wide medical database managed by the Hospital Authority (HA). Patients were followed up until 31 December 2016. [J Bone Miner Res 2020, doi: 10.1002/jbmr.4030]

At baseline, 4,041 patients exposed to any N-BPs (ie, alendronate, ibandronate, risedronate and zoledronate) during the study period were matched with 11,802 patients who received no anti-osteoporotic treatment. More than 15 percent (15.8 percent) and 14.3 percent of patients with and without N-BP treatment, respectively, received seasonal influenza vaccine in the past year or pneumococcal vaccine on/before the index date.

Likewise, 1,284 patients with N-BP treatment were matched with 507 patients with non-N-BP anti-osteoporotic treatment, with strontium ranelate, salcatonin, denosumab, teriparatide and raloxifene used in 166, 161, 135, 38 and 7 patients, respectively.

In patients who received N-BPs vs no anti-osteoporotic treatment, the incidence of pneumonia and pneumonia mortality was 6.9 vs 9.0 per 100 person-years and 2.3 vs 3.5 per 100 person-years, respectively, during a median of 2.7 years of follow-up.

Patients treated with N-BPs had a 24 percent lower risk of incident pneumonia (hazard ratio [HR], 0.76; 95 percent confidence interval [Cl], 0.70 to 0.83; p<0.001) vs those with no anti-osteoporotic treatment, translating to an absolute risk difference (ARD) of 0.02 and number needed to treat (NNT) of 46.

A significant risk reduction in pneumonia mortality was also observed in patients who received N-BPs vs no anti-osteoporotic treatment (HR, 0.65; 95 percent CI, 0.56 to 0.75; p<0.001).

“The study included mainly alendronate-exposed patients [81.6 percent],” the researchers noted. Among these patients, similar risk reductions in incident pneumonia (HR, 0.74; 95 percent CI, 0.67 to 0.81; p<0.001) and pneumonia mortality (HR, 0.63; 95 percent CI, 0.54 to 0.74; p<0.001) were observed vs no anti-osteoporotic treatment.

Of note, reductions in risk of incident pneumonia and pneumonia mortality with N-BPs vs no anti-osteoporotic treatment remained significant regardless of gender and vaccination status (incident pneumonia: female, p<0.001; male, p=0.009; vaccination, p=0.007; no vaccination, p<0.001) (pneumonia mortality: female: p<0.001; male, p=0.025; vaccination, p=0.055; no vaccination, p<0.001).

In a secondary analysis, consistent reductions in risk of incident pneumonia and associated mortality were seen with N-BPs vs non-N-BP anti-osteoporotic treatment (incident pneumonia: HR, 0.68; 95 percent CI, 0.53 to 0.87; p=0.002) (pneumonia mortality: HR, 0.60; 95 percent CI, 0.41 to 0.89; p=0.01).

According to the researchers, the study’s results suggest that N-BPs could confer additional protection against pneumonia to compensate for the reported shortage and low acceptance of vaccine, as well as the high cost of large-scale vaccination programmes. “Drug repositioning of N-BPs as a pneumonia prevention drug, especially in high-risk groups [eg, patients with osteoporosis], may be of public health importance,” they suggested.  “Further randomized clinical trials may be warranted to further validate our findings.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
In patients with heart failure with preserved ejection fraction (HFpEF), angiotensin-neprilysin inhibition with sacubitril/valsartan confers better renoprotection than valsartan alone, reducing the risk of adverse renal events and the speed of decline in estimated glomerular filtration rate (eGFR), a study has found.
5 days ago
Dupilumab solution for injection (pre-filled syringe) 200 mg/1.14 mL and 300 mg/2 mL
Jairia Dela Cruz, 5 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Dr. Tai-Pang Ip, Dr. Sze-Hung Wong, 04 Sep 2020
Osteoporosis (OP) is a disabling condition associated with significant morbidity and mortality. Management of OP requires a multidisciplinary approach, with choice of treatment based on patients’ fracture risk. At a virtual symposium organized by the Osteoporosis Society of Hong Kong (OSHK), Dr Tai-Pang Ip, Specialist in Endocrinology, Diabetes and Metabolism in Hong Kong, and Dr Sze-Hung Wong, Specialist in Orthopaedics and Traumatology in Hong Kong, discussed the diagnosis and management of OP in primary care and the role of antiresorptive and bone-forming agents in treatment of OP in high-risk patients.